Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVaxys TechnologyBVAXF Buyback Yield % is 0.00 as of Aug. 19, 2026. Among 717 Biotechnology companies, BioVaxys Technology ranks worse than 90.93% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
BioVaxys Technology Buyback Yield % Historical Data
* Premium members only.
The historical data trend for BioVaxys Technology's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BVAXF vs BPTH, AZTR, CLDI: Buyback Yield % Comparison
For the Biotechnology subindustry, BioVaxys Technology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVaxys Technology Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where BioVaxys Technology's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVaxys Technology (BVAXF) has a Buyback Yield % of 0.00 as of Aug. 19, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioVaxys Technology and its competitors. According to the industry distribution chart, BioVaxys Technology ranks #652 out of 717 companies in the Biotechnology industry, placing it in the top 90.9%.
Is BioVaxys Technology's Buyback Yield % too high?
BioVaxys Technology's current Buyback Yield % is 0.00. Based on the distribution chart, BioVaxys Technology ranks #652 out of 717 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does BioVaxys Technology's Buyback Yield % compare to BPTH and AZTR?
According to the Biotechnology industry distribution chart, BioVaxys Technology ranks #652 out of 717 companies for Buyback Yield %. This places BioVaxys Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioVaxys Technology and its competitors. BioVaxys Technology's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (BVAXF) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BioVaxys Technology (BVAXF), the current Buyback Yield % is 0.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVAXF has been successfully added to your 
